Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1836445 | PMC |
| http://dx.doi.org/10.1136/bmj.298.6680.1052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.
Ann Oncol
January 2025
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer outcomes. The goal of this study was to provide updated data regarding the formulary availability, out-of-pocket costs, and accessibility of cancer medicines in countries across the full spectrum of economic development areas.
View Article and Find Full Text PDFEnsuring safe and effective pharmacotherapy: The role of "community pharmacology" in attaining "health for all" from the Indian perspective.
J Family Med Prim Care
December 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Kalyani, Kalyani, West Bengal, India.
The novel approach of "Community Pharmacology" integrates pharmacological principles with community health to achieve the "Health for all" goal through safe and efficient health care. Pharmacovigilance, medication errors (ME), irrational prescriptions, and antimicrobial resistance in the community could be the key areas. Though life expectancy and other health indicators have improved in India, the disparity between rural and urban quality healthcare access should be addressed.
View Article and Find Full Text PDF[Off-label psychopharmacological prescription in thirteen forensic outpatient clinics].
Tijdschr Psychiatr
January 2025
Article Synopsis
- The study examines the prevalence of off-label prescribing in outpatient forensic treatment, revealing that 72.0% of prescriptions were off-label.
- More than half (51.4%) of these off-label prescriptions were informed by existing guidelines and formularies, while 20.6% were not.
- A significant finding was that in 84.7% of the cases where off-label prescriptions did not follow guidelines, pharmacists were not consulted prior to prescribing.
Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice.
J Pharm Technol
December 2024
Department of Medicine, Larner College of Medicine, The University of Vermont, Burlington, VT, USA.
Infliximab is an anti-tumor necrosis factor agent used to treat rheumatologic disease. Evidence on the safety of switching to biosimilars and the associated risk factors for flares/loss of disease control within rheumatology is limited. The primary objective is to evaluate nonmedical switches from reference infliximab to biosimilars in rheumatology on risks and level of disease control.
View Article and Find Full Text PDFPrescribing Patterns and Off-Label Use of Gabapentinoid Agents at Dhulikhel Hospital, Nepal: A Cross-Sectional Study.
J Pain Res
December 2024
Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Purpose: Gabapentinoids are mainly prescribed for neuropathic pain and certain seizure disorders, but their off-label use has increased significantly. This rise raises concerns about the insufficient evidence supporting some applications, as well as potential risks of misuse, dependence, and adverse effects. The study aims to examine the prescribing patterns and off-label use of gabapentinoids at Dhulikhel Hospital (DH), Nepal, focusing on understanding the extent of off-label practices and patient knowledge regarding their medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!